Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06536725
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-30
Brief Title:
Observation of Clinical Consistency of Organoid-chips Drug Sensitivity in Chemotherapy for PCa With Visceral Metastasis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Observation of Clinical Consistency of Organoid-on-chips Drug Sensitivity Detection in Chemotherapy for Prostate Cancer Patients With Visceral Metastasis
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This project plans to establish an organoid chip model of prostate cancer patients with internal organ metastasis from surgical or biopsy tissue sources and test the sensitivity of commonly used chemotherapy drugs based on organoid chip drug sensitivity testing technology to screen out sensitive individualized treatment plans
Detailed Description:
This project plans to establish an organoid chip model of prostate cancer patients with internal organ metastasis from surgical or biopsy tissue sources and test the sensitivity of commonly used chemotherapy drugs based on organoid chip drug sensitivity testing technology to screen out sensitive individualized treatment plansThe final medication regimen for patients is determined by doctors based on their experience and in vitro drug sensitivity results The actual clinical efficacy of medication is tracked for patients and the organoid chip drug sensitivity detection model is analyzed as a predictor of the sensitivity specificity and accuracy of anti-tumor chemotherapy drugs providing data reference for clinical applicationsAt the same time analyze the accuracy of drug sensitivity testing results and clinical empirical medicationIf patients are treated with a chemotherapy combined with immunotherapy regimen the in vitro sensitivity of immune drugs will be determined using organoid-immune co-culture technology and exploratory research on the predictive performance of immune models will be conducted in conjunction with clinical medication
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None